Key points are not available for this paper at this time.
As oncologists reflecting on the past 20 years of medical oncology, we recognize many therapeutic advances that have changed our practice and, above all, saved patients' lives. For epithelial ovarian cancer (EOC), the introduction of poly-ADP ribose polymerase inhibitors (PARPi) is one such historic achievement, comparable with the implementation of anti-human epidermal growth factor receptor 2 (HER2) antibodies for the treatment of HER2-positive breast cancer.
Bartoletti et al. (2021) studied this question.